Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025

Core Insights - Krystal Biotech is focused on developing redosable gene therapies for rare skin diseases, with a strong late-stage clinical pipeline and an expanding portfolio [6][8] - Redmile Group increased its stake in Krystal Biotech by purchasing 16,317 shares, valued at approximately $3.43 million, reflecting confidence in the company's growth potential [2][7] Company Overview - Current share price is $261.80, with a market capitalization of $7.6 billion [4] - The company reported a total revenue of $373.2 million and a net income of $198.9 million for the trailing twelve months (TTM) [4] Financial Performance - Krystal Biotech's revenue for the fourth quarter from its product VYJUVEK reached $107.1 million, contributing to a total of $389.1 million for the full year 2025 [7][9] - The company achieved a gross margin of 94% and a net income of $204.8 million for the full year 2025, more than double the previous year's figure [9] Investment Implications - Krystal Biotech now represents 12.3% of Redmile Group's 13F-reportable assets under management (AUM), indicating a significant investment conviction [7][10] - The stock has increased by 44% over the past year, outperforming the S&P 500, which gained approximately 13% in the same period [7][11] Pipeline and Strategy - The company is advancing a differentiated pipeline of redosable gene therapies targeting both dermatological and respiratory indications, with a focus on addressing unmet medical needs [6][8] - Krystal Biotech's lead product, beremagene geperpavec (B-VEC), is in late-stage clinical trials for dystrophic epidermolysis bullosa [8]